EVERSANA, distributor and provider of commercialization services for the life sciences industry, announced a merger with digital health company Waltz Health, creating a unified platform designed to transform how pharmaceutical products reach patients.
The merger integrates EVERSANA’s distribution network with Waltz Health’s AI-driven drug-price marketplaces and direct-to-payer technology, enhancing the company’s ability to manage complex supply chains for specialty and high-cost therapies, including GLP-1 drugs. The combined platform is intended to lower drug costs, improve patient access, and streamline the distribution process.
Mark Thierer, co-founder and CEO of Waltz Health and chairman of EVERSANA, will lead the merged organization as CEO. Thierer previously served as CEO of OptumRx following UnitedHealth Group’s $13 billion acquisition of Catamaran.
“This merger strengthens EVERSANA’s position as a pharmaceutical distributor,” Thierer said. “By combining our distribution infrastructure with Waltz Health’s payer-connected technology, we can deliver therapies faster, more efficiently, and more affordably to patients.”
The combined company expands EVERSANA’s distribution capabilities across:
- Pharma Commercialization: Integration of patient services, field teams, digital marketing, reimbursement support, and real-world evidence.
- Payer Connectivity: Direct-to-payer and direct-to-patient channels, giving manufacturers access to millions of insured lives.
- Drug Affordability & Adherence: AI-driven pharmacy routing, net-price models, and copay optimization to reduce patient abandonment.
- Specialty Pharmacy Network: Waltz Connect provides a fully integrated, URAC-accredited specialty pharmacy infrastructure for high-cost and limited-distribution therapies.
Serving more than 650 life sciences organizations globally, EVERSANA is leveraging the merger to tackle rising distribution challenges in the pharmaceutical industry, including supply chain complexity, patient affordability, and fragmented channels.
“With Waltz Health integrated into our distribution network, EVERSANA is redefining how therapies move from manufacturers to patients and payers, delivering greater efficiency, transparency, and value across the supply chain,” Thierer said.
Don’t miss any content from Distribution Strategy Group. Join our list.
